The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis
The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis
复制标题
SLCO1B1、载脂蛋白 E 和 CYP2C9 基因与氟伐他汀脂质反应之间的关联：一项荟萃分析
DOI：
10.1097/fpc.0000000000000356
复制
发表时间：
2018-12
影响因子：
2.6
通讯作者：
Cui Y
中科院分区：
文献类型：
--
作者：
Xiang Q;Zhang X;Ma L;Hu K;Zhang Z;Mu G;Xie Q;Chen S;Cui Y
目的探讨SLCO1B1、载脂蛋白E(ApoE)和细胞色素P450 2C9基因分型对氟伐他汀降脂疗效的影响。方法我们在PubMed、Embase和Cochrane图书馆数据库上进行了电子搜索，以确定截至2017年10月发表的研究。报告总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)和高密度脂蛋白(高密度脂蛋白)的95%可信区间(CI)的效果估计的研究被包括在内，以便可以比较不同的基因类别。用加权平均差(WMD)对疗效估计进行汇总。结果共纳入6项研究，涉及1171名个体。我们注意到SLCO1B1521TT患者与521TC或CC相比，TC(WMD：−2.98；95%CI：−5.12至−0.84；P=0.006)和低密度脂蛋白(WMD：−5.58；95%CI：−10.64至−0.52；P=0.031)的变化更大。载脂蛋白E*2/*3携带者的高密度脂蛋白水平明显高于载脂蛋白E*3/3(WMD18.76；95%CI：8.97~28.55；P<；0.001)和ApoE*3/*4或*4/*4(WMD22.51；95%CI0.98~44.04；P=0.040)。最后，CYP2C9基因分型与氟伐他汀对TC、甘油三酯和低密度脂蛋白的影响没有相关性。结论SLCO1B1和ApoE基因多态性可能影响氟伐他汀的降脂疗效，而CYP2C9基因与氟伐他汀的疗效无关。
Objective The aim of this study was to determine the impact of the SLCO1B1, apolipoprotein E (ApoE), and CYP2C9 genotypes on the lipid-lowering efficacy of fluvastatin. Methods We performed electronic searches on the PubMed, Embase, and Cochrane Library databases to identify studies published through October 2017. Studies that reported the effect estimates with 95% confidence intervals (CIs) of total cholesterol (TC), triglyceride, low-density lipoprotein (LDL), and high-density lipoprotein were included so that the different genotype categories could be compared. Weighted mean difference (WMD) was used to summarize the effect estimates. Results Six studies, involving a total of 1171 individuals, were included in the final analysis. We noted that the patient carrier SLCO1B1 521TT was associated with greater change in TC (WMD: −2.98; 95% CI: −5.12 to −0.84; P=0.006) and LDL (WMD: −5.58; 95% CI: −10.64 to −0.52; P=0.031) compared with 521TC or CC. Furthermore, the patient carrier ApoE*2/*3 showed more change in high-density lipoprotein compared with ApoE*3/*3 (WMD: 18.76; 95% CI: 8.97–28.55; P<0.001) and ApoE*3/*4 or *4/*4 (WMD: 22.51; 95% CI: 0.98–44.04; P=0.040). Finally, the CYP2C9 genotypes showed no correlation with the effects of fluvastatin on TC, triglyceride, and LDL. Conclusion The findings of this study suggested that the SLCO1B1 and ApoE polymorphisms could influence the lipid-lowering effect of fluvastatin, whereas the CYP2C9 genotypes were not associated with the therapeutic effects of fluvastatin.
登录
查看更多内容
影响因子：
15.8
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
DOI：
--
发表时间：
2016
期刊：
--
影响因子：
--
作者：
Arno W. Hoes;M. Cooney;Michael Stephen Hall;F. D. R. Hobbs;W. M. M. Verschuren-W.-M.-M.-Verschuren-2247710788
通讯作者：
Arno W. Hoes;M. Cooney;Michael Stephen Hall;F. D. R. Hobbs;W. M. M. Verschuren-W.-M.-M.-Verschuren-2247710788
影响因子：
3.6
作者：
Kopplow, K;Letschert, K;Keppler, D
通讯作者：
Keppler, D
影响因子：
2.1
作者：
Couvert, Philippe;Giral, Philippe;Carrie, Alain
通讯作者：
Carrie, Alain
影响因子：
24
作者：
C. Ballantyne;J. Herd;E. Stein;L. Ferlic;J. Dunn;A. Gotto;A. Marian
通讯作者：
C. Ballantyne;J. Herd;E. Stein;L. Ferlic;J. Dunn;A. Gotto;A. Marian